CervoMed Inc., a clinical-stage biotechnology company, engages in the development and commercialization of drug treatments for neurodegenerative diseases. The company is headquartered in Boston, Massachusetts.
| Revenue (TTM) | $2.09M |
| Gross Profit (TTM) | $-20.02M |
| EBITDA | — |
| Operating Margin | -1489.00% |
| Return on Equity | -132.80% |
| Return on Assets | -72.40% |
| Revenue/Share (TTM) | $0.23 |
| Book Value | $1.15 |
| Price-to-Book | 3.14 |
| Price-to-Sales (TTM) | 15.16 |
| EV/Revenue | 307.67 |
| EV/EBITDA | 1.64 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -99.60% |
| Shares Outstanding | $9.26M |
| Float | $6.06M |
| % Insiders | 29.55% |
| % Institutions | 19.11% |
Interim biomarker data accepted for presentation at the 19 th Clinical Trials on Alzheimer's Disease (CTAD) conference
Latest findings on neflamapimod to be featured in presentations demonstrating its impact on dementia with Lewy bodies (DLB) disease progression, biomarkers of neurodegeneration, and basal forebrain atrophy, as well as optimal dosing strategies
BOSTON, June 22, 2026 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical-stage biotechnology company developing treatments for age-related brain disorders (CervoMed or the Company), today announced the closing of its previously announced registered direct offering priced at-the-market under Nasdaq rules for the purchase and sale of 2,500,000 shares of common stock at a purchase price of $4.00 per share.
BOSTON, June 18, 2026 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical-stage biotechnology company developing treatments for age-related brain disorders (CervoMed or the Company), today announced that it has entered into definitive agreements for the purchase and sale of 2,500,000 shares of common stock at a purchase price of $4.00 per share in a registered direct offering priced at-the-market under Nasdaq rules. The closing of the offering is expected to occur on or about June 22, 2026, subject to the satisfaction of customary closing conditions.
BOSTON, June 18, 2026 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical-stage biotechnology company developing treatments for age-related brain disorders (CervoMed or the Company), today announced that it has received a notice of allowance from the United States Patent and Trademark Office (USPTO) related to a new patent protecting the Company's use of its drug candidate, neflamapimod, for the treatment of dementia with Lewy bodies (DLB) in patients with no substantial Alzheimer's disease-like tau pathology, also known as “pure DLB”. The patent will cover the treatment of DLB without substantial tau pathology, which can be characterized by plasma levels of pTau or brain imaging, and is expected to provide intellectual property protection into 2042 and potentially longer with patent term extension.
BOSTON, June 12, 2026 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical-stage biotechnology company developing treatments for age-related brain disorders (CervoMed or the Company), today announced that Company management will participate in a fireside chat and one-on-one investor meetings at the H.C. Wainwright 7th Annual Neuro Perspectives Expert Summit, being held virtually on Monday, June 15, 2026.
Continued progress towards initiating planned Phase 3 trial evaluating neflamapimod in patients with dementia with Lewy bodies in second half of 2026, subject to financing
Results consistent with pre-clinical studies demonstrating that, in the early stages of the neurodegenerative process, disease progression in the basal forebrain is reversible
Update will include new MRI analyses from the Phase 2b RewinD-LB clinical trial, status of global regulatory discussions, and finalized Phase 3 trial design
